These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31286464)

  • 1. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
    Shih YT; Xu Y; Chien CR; Kim B; Shen Y; Li L; Geynisman DM
    Pharmacoeconomics; 2019 Dec; 37(12):1495-1507. PubMed ID: 31286464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of renal cell carcinoma in the US: Part II--an updated analysis.
    Shih YC; Chien CR; Xu Y; Pan IW; Smith GL; Buchholz TA
    Pharmacoeconomics; 2011 Apr; 29(4):331-41. PubMed ID: 21395352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
    Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
    Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
    Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
    J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 7. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
    Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
    Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.
    Saad AM; Gad MM; Al-Husseini MJ; Ruhban IA; Sonbol MB; Ho TH
    Clin Genitourin Cancer; 2019 Feb; 17(1):46-57.e5. PubMed ID: 30391138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.
    Brown ML; Riley GF; Potosky AL; Etzioni RD
    Med Care; 1999 Dec; 37(12):1249-59. PubMed ID: 10599606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of illness associated with hepatocellular carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Shah S; Thompson D
    J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data.
    Bhandari NR; Kale HP; Carroll NV; McAdam-Marx C; Ounpraseuth ST; Tilford JM; Kamel MH; Kent EE; Payakachat N
    Urol Oncol; 2022 Jul; 40(7):347.e17-347.e27. PubMed ID: 35643842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review.
    Chien CR; Geynisman DM; Kim B; Xu Y; Shih YT
    Pharmacoeconomics; 2019 Mar; 37(3):301-331. PubMed ID: 30467701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, predictors, costs, and outcome of renal cell carcinoma after kidney transplantation: USRDS experience.
    Hurst FP; Jindal RM; Graham LJ; Falta EM; Elster EA; Stackhouse GB; Agodoa LY; Lentine KL; Salifu MO; Abbott KC
    Transplantation; 2010 Oct; 90(8):898-904. PubMed ID: 21248500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
    Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
    Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
    Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
    Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of trends in the cost of initial cancer treatment.
    Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
    J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.